Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?

Author:

Lathia Chetan D.1

Affiliation:

1. Clinical Pharmacology, Bayer Corporation, West Haven, CT 06516, USA

Abstract

As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity. Biomarkers are measurements based on molecular pharmacology and/or pathophysiology of the disease being evaluated that may assist with decision-making in various phases of drug development. The utility of biomarkers in the development of drugs is described in this review. Additionally, the utility of pharmacokinetic data in drug development is described. Development of biomarkers may help reduce the cost of drug development by allowing key decisions earlier in the drug development process. Additionally, biomarkers may be used to select patients who have a high likelihood of benefit or they could be used by clinicians to evaluate the potential for efficacy after start of treatment.

Publisher

Hindawi Limited

Subject

Biochemistry, medical,Clinical Biochemistry,Genetics,Molecular Biology,General Medicine

Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Translational medicine and biomarkers;Basic Principles of Drug Discovery and Development;2021

2. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy;Journal of Controlled Release;2020-11

3. Personalized Diagnosis and Therapy;Drug Discovery and Evaluation: Pharmacological Assays;2016

4. An Integrative Approach to Biomarker Development in Psoriatic Arthritis;The Journal of Rheumatology Supplement;2015-11-01

5. Industry perspectives on biomarker qualification;Clinical Pharmacology & Therapeutics;2015-10-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3